Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06397131 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine the Safety and Efficacy of NT-501 With MHFM
A Phase 3 study of Macular Telangiectasia Type 2, sponsored by Neurotech Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT06397131 is a Phase 3 study of Macular Telangiectasia Type 2 that is active but no longer recruiting, run by Neurotech Pharmaceuticals. The registered enrollment target is 12 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT06397131, a Phase 3 study of Macular Telangiectasia Type 2, is active but no longer recruiting, sponsored by Neurotech Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is to determine the long-term levels of CNTF, and the clinical safety and efficacy of the NT-501 implants with the Medica Hollow Fiber Membrane (MHFM) in participants with macular telangiectasia type 2.
Conditions Studied
Interventions
- COMBINATION_PRODUCT NT-501 CNTF Implant
Study Locations (3)
California
- Bay Area Retina Associates, A Medical Group - Walnut Creek
Michigan
- Foundation for Vision Research - Grand Rapids
Texas
- Retina Consultants of Texas - Bellaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2026-07-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06397131
The ClinicalTrials.gov registry entry for NCT06397131 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurotech Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Macular Telangiectasia Type 2 appearing as the primary indexed condition, and to 1 intervention - of which NT-501 CNTF Implant is the first listed.
NCT06397131 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT06397131 about?
NCT06397131 is a clinical study titled "A Study to Determine the Safety and Efficacy of NT-501 With MHFM". This study is to determine the long-term levels of CNTF, and the clinical safety and efficacy of the NT-501 implants with the Medica Hollow Fiber Membrane (MHFM) in participants with macular telangiectasia type 2.
What is the current status of trial NCT06397131?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2025-03-06. Estimated completion is 2026-07-24.
What conditions does trial NCT06397131 study?
This clinical trial studies the following conditions: Macular Telangiectasia Type 2.
What interventions are being tested in trial NCT06397131?
The interventions under investigation include: NT-501 CNTF Implant (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06397131?
This trial is sponsored by Neurotech Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06397131 being conducted?
This trial has 3 study locations across California, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Telangiectasia Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.